Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates
Cefiderocol is a catechol-substituted siderophore cephalosporin combining rapid penetration into the periplasmic space with increased stability against β-lactamases. This study provides additional data on the in vitro antimicrobial activity of cefiderocol and commercially available comparators again...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/11/2/187 |
| _version_ | 1797483383406723072 |
|---|---|
| author | Clara Ballesté-Delpierre Ángel Ramírez Laura Muñoz Christopher Longshaw Ignasi Roca Jordi Vila |
| author_facet | Clara Ballesté-Delpierre Ángel Ramírez Laura Muñoz Christopher Longshaw Ignasi Roca Jordi Vila |
| author_sort | Clara Ballesté-Delpierre |
| collection | DOAJ |
| description | Cefiderocol is a catechol-substituted siderophore cephalosporin combining rapid penetration into the periplasmic space with increased stability against β-lactamases. This study provides additional data on the in vitro antimicrobial activity of cefiderocol and commercially available comparators against an epidemiologically diverse collection of <i>Acinetobacter baumannii</i> clinical isolates. Antimicrobial susceptibility was tested using pre-prepared frozen 96-well microtiter plates containing twofold serial dilutions of: cefepime, ceftazidime/avibactam, imipenem/relebactam, ampicillin/sulbactam, meropenem, meropenem/vaborbactam, ciprofloxacin, minocycline, tigecycline, trimethoprim/sulfamethoxazole and colistin using the standard broth microdilution procedure in cation-adjusted Mueller–Hinton broth (CAMHB). For cefiderocol, iron-depleted CAMHB was used. A collection of 113 clinical strains of <i>A. baumannii</i> isolated from Argentina, Azerbaijan, Croatia, Greece, Italy, Morocco, Mozambique, Peru and Spain were included. The most active antimicrobial agents against our collection were colistin and cefiderocol, with 12.38% and 21.23% of non-susceptibility, respectively. A high proportion of multidrug-resistant (76.77%) and carbapenem-resistant (75.28%) <i>A. baumannii</i> isolates remained susceptible to cefiderocol, which was clearly superior to novel β-lactam/β-lactamase inhibitor combinations. Cefiderocol-resistance was higher among carbapenem-resistant isolates and isolates belonging to ST2, but could not be associated with any particular resistance mechanism or clonal lineage. Our data suggest that cefiderocol is a good alternative to treat infections caused by MDR <i>A. baumanni</i>, including carbapenem-resistant strains. |
| first_indexed | 2024-03-09T22:46:11Z |
| format | Article |
| id | doaj.art-2800353e776746aaa96dbaeaa5205992 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-09T22:46:11Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-2800353e776746aaa96dbaeaa52059922023-11-23T18:27:54ZengMDPI AGAntibiotics2079-63822022-01-0111218710.3390/antibiotics11020187Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical IsolatesClara Ballesté-Delpierre0Ángel Ramírez1Laura Muñoz2Christopher Longshaw3Ignasi Roca4Jordi Vila5Department of Clinical Microbiology, ISGlobal, Hospital Clínic—Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, SpainDepartment of Clinical Microbiology, ISGlobal, Hospital Clínic—Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, SpainDepartment of Clinical Microbiology, ISGlobal, Hospital Clínic—Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, SpainInfectious Diseases, Shionogi B.V., London WC2B 6UF, UKDepartment of Clinical Microbiology, ISGlobal, Hospital Clínic—Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, SpainDepartment of Clinical Microbiology, ISGlobal, Hospital Clínic—Universitat de Barcelona, Rosselló 149-153, 08036 Barcelona, SpainCefiderocol is a catechol-substituted siderophore cephalosporin combining rapid penetration into the periplasmic space with increased stability against β-lactamases. This study provides additional data on the in vitro antimicrobial activity of cefiderocol and commercially available comparators against an epidemiologically diverse collection of <i>Acinetobacter baumannii</i> clinical isolates. Antimicrobial susceptibility was tested using pre-prepared frozen 96-well microtiter plates containing twofold serial dilutions of: cefepime, ceftazidime/avibactam, imipenem/relebactam, ampicillin/sulbactam, meropenem, meropenem/vaborbactam, ciprofloxacin, minocycline, tigecycline, trimethoprim/sulfamethoxazole and colistin using the standard broth microdilution procedure in cation-adjusted Mueller–Hinton broth (CAMHB). For cefiderocol, iron-depleted CAMHB was used. A collection of 113 clinical strains of <i>A. baumannii</i> isolated from Argentina, Azerbaijan, Croatia, Greece, Italy, Morocco, Mozambique, Peru and Spain were included. The most active antimicrobial agents against our collection were colistin and cefiderocol, with 12.38% and 21.23% of non-susceptibility, respectively. A high proportion of multidrug-resistant (76.77%) and carbapenem-resistant (75.28%) <i>A. baumannii</i> isolates remained susceptible to cefiderocol, which was clearly superior to novel β-lactam/β-lactamase inhibitor combinations. Cefiderocol-resistance was higher among carbapenem-resistant isolates and isolates belonging to ST2, but could not be associated with any particular resistance mechanism or clonal lineage. Our data suggest that cefiderocol is a good alternative to treat infections caused by MDR <i>A. baumanni</i>, including carbapenem-resistant strains.https://www.mdpi.com/2079-6382/11/2/187<i>Acinetobacter baumannii</i>antibiotic resistancecarbapenemMDRtrojan horsecefiderocol |
| spellingShingle | Clara Ballesté-Delpierre Ángel Ramírez Laura Muñoz Christopher Longshaw Ignasi Roca Jordi Vila Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates Antibiotics <i>Acinetobacter baumannii</i> antibiotic resistance carbapenem MDR trojan horse cefiderocol |
| title | Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates |
| title_full | Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates |
| title_fullStr | Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates |
| title_full_unstemmed | Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates |
| title_short | Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates |
| title_sort | assessment of in vitro cefiderocol susceptibility and comparators against an epidemiologically diverse collection of i acinetobacter baumannii i clinical isolates |
| topic | <i>Acinetobacter baumannii</i> antibiotic resistance carbapenem MDR trojan horse cefiderocol |
| url | https://www.mdpi.com/2079-6382/11/2/187 |
| work_keys_str_mv | AT claraballestedelpierre assessmentofinvitrocefiderocolsusceptibilityandcomparatorsagainstanepidemiologicallydiversecollectionofiacinetobacterbaumanniiiclinicalisolates AT angelramirez assessmentofinvitrocefiderocolsusceptibilityandcomparatorsagainstanepidemiologicallydiversecollectionofiacinetobacterbaumanniiiclinicalisolates AT lauramunoz assessmentofinvitrocefiderocolsusceptibilityandcomparatorsagainstanepidemiologicallydiversecollectionofiacinetobacterbaumanniiiclinicalisolates AT christopherlongshaw assessmentofinvitrocefiderocolsusceptibilityandcomparatorsagainstanepidemiologicallydiversecollectionofiacinetobacterbaumanniiiclinicalisolates AT ignasiroca assessmentofinvitrocefiderocolsusceptibilityandcomparatorsagainstanepidemiologicallydiversecollectionofiacinetobacterbaumanniiiclinicalisolates AT jordivila assessmentofinvitrocefiderocolsusceptibilityandcomparatorsagainstanepidemiologicallydiversecollectionofiacinetobacterbaumanniiiclinicalisolates |